摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-tert-butyl-5-((4-(3-chloro-4-(3-(2-hydroxy-2-methylpropyl)ureido)benzoyl)piperazin-1-yl)methyl)furan-2-carboxamide | 1209996-20-2

中文名称
——
中文别名
——
英文名称
N-tert-butyl-5-((4-(3-chloro-4-(3-(2-hydroxy-2-methylpropyl)ureido)benzoyl)piperazin-1-yl)methyl)furan-2-carboxamide
英文别名
N-tert-butyl-5-[[4-[3-chloro-4-[(2-hydroxy-2-methylpropyl)carbamoylamino]benzoyl]piperazin-1-yl]methyl]furan-2-carboxamide
N-tert-butyl-5-((4-(3-chloro-4-(3-(2-hydroxy-2-methylpropyl)ureido)benzoyl)piperazin-1-yl)methyl)furan-2-carboxamide化学式
CAS
1209996-20-2
化学式
C26H36ClN5O5
mdl
——
分子量
534.055
InChiKey
FNQNATWYKLCOJX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    37
  • 可旋转键数:
    8
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    127
  • 氢给体数:
    4
  • 氢受体数:
    6

文献信息

  • 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES
    申请人:Cooke Andrew John
    公开号:US20120015958A1
    公开(公告)日:2012-01-19
    The present invention relates to 1-(4-ureidobenzoyl)piperazine derivatives having the general Formula I (We bring to your attention that formula I is not provided on this electronic version as it is provided in the abstract of the paper copy) Wherein R 1 is (C 1-8 )alkyl, (C 3-8 )cycloalkyl or (C 3-8 )cycloalkyl(C 1-3 )alkyl, each of which may be substituted by hydroxy, cyano or halogen; R 2 represents 1 or 2 optional halogens; R 3 is (C 1-6 )alkyl, (C 3-6 )cycloalkyl or (C 3-6 )cycloalkyl(C 1-3 )alkyl, each of which may be substituted by one or more halogens; A represents a heteroaryl ring system comprising 1-3 heteroatoms selected from N, O and S, which ring system is 5- or 6-membered when X is C, and 5-membered when X is N; n is 1 or 2; or a pharmaceutically acceptable salt thereof; to pharmaceutical compositions comprising the same, and to the use of a these 1-(4-ureidobenzoyl)piperazine derivatives for the manufacture of a medicament for treating or preventing atherosclerosis and related disorders associated with cholesterol and bile acids transport and metabolism.
    本发明涉及具有一般式I的1-(4-尿素基苯甲酰基)哌嗪生物(请注意,由于在电子版中没有提供公式I,因此不提供公式I)。其中R1为(C1-8)烷基,(C3-8)环烷基或(C3-8)环烷基(C1-3)烷基,每种基团均可被羟基,基或卤素取代;R2表示1或2个可选的卤素;R3为(C1-6)烷基,(C3-6)环烷基或(C3-6)环烷基(C1-3)烷基,每种基团均可被一个或多个卤素取代;A表示含有1-3个从N、O和S中选择的杂环原子的杂环环系,当X为C时,该环系为5-或6-成员环,当X为N时,该环系为5-成员环;n为1或2;或其药学上可接受的盐;以及包含它们的制药组合物,并用于制造用于治疗或预防与胆固醇胆汁酸转运和代谢相关的动脉粥样硬化和相关疾病的药物的这些1-(4-尿素基苯甲酰基)哌嗪生物的用途。
  • US8759352B2
    申请人:——
    公开号:US8759352B2
    公开(公告)日:2014-06-24
查看更多